Front Row Advisors’s Maravai LifeSciences MRVI Stock Holding History

Front Row Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$7K	–	939
2022 Q1	$7K	Hold	200	–	–	﹤0.01%	643
2021 Q4	$8K	Buy	+200	New	+$8.1K	﹤0.01%	638

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Front Row Advisors's MRVI Position: Q2 2022 in Review

Front Row Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2022, closing a stake of 200 shares — an estimated $7K sold.

Front Row Advisors first reported a position in MRVI in Q4 2021 and held it in 2 quarters. The position peaked at $8K in Q4 2021. 216 funds tracked by Wall St. Rank hold MRVI as of Q2 2022.

Front Row Advisors reported no remaining Maravai LifeSciences position as of Q2 2022 after selling out during the quarter.
Front Row Advisors sold 200 Maravai LifeSciences shares in Q2 2022, an estimated $7K.
Front Row Advisors first reported a position in Maravai LifeSciences in Q4 2021 and held it in 2 quarters.
Front Row Advisors's Maravai LifeSciences position peaked at $8K in Q4 2021.
216 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2022.

Based on Front Row Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.